Literature DB >> 17932354

Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation.

Jie Lin1, Gary E Swan, Peter G Shields, Neal L Benowitz, Jian Gu, Christopher I Amos, Mariza de Andrade, Margaret R Spitz, Xifeng Wu.   

Abstract

The rationale behind gene-disease association studies is that genetic variants (polymorphisms) result in alterations in intermediate phenotypes. However, genotype-phenotype correlations have not been established for most polymorphisms. In this study, we correlated genotype data of genes involved in the nucleotide excision repair pathway with mutagen sensitivity phenotype, quantified by benzo(a)pyrene diol epoxide (BPDE)-induced chromatid breaks in peripheral blood lymphocytes in 422 healthy subjects recruited into a twin study that included 138 pairs of monozygotic twins, 51 pairs of dizygotic twins, and 44 siblings. Among a panel of single nucleotide polymorphisms examined, we found that BPDE sensitivity was modified by individual polymorphisms in XPC, RAD23B, and XPA genes. Specific haplotypes and diplotypes of XPC also modified BPDE sensitivity profiles. In addition, a more consistent and stronger correlation was observed between mutagen sensitivity phenotype and the combination of multiple polymorphisms in the nucleotide excision repair pathway. Specifically, when XPC-PAT, XPC Lys939Gln, XPA A23G, and RAD23B Val249Ala were analyzed together, we observed a significant dose-response relationship between increasing mutagen sensitivity with increasing number of adverse alleles: mutagen sensitivity for those carrying zero to two, three to five, and six or more adverse alleles were 0.64, 0.68, and 1.06, respectively (P for trend = 0.008), and the results remained significant after adjusting for multiple comparisons. Using individuals carrying zero to two adverse alleles as the reference group, the risks of being mutagen sensitive (mutagen sensitivity values greater than the median) were 1.05 (95% confidence interval, 0.68-1.64) and 4.48 (95% confidence interval, 1.21-16.61) for those carrying three to five and six or more adverse alleles, respectively. Analyses of the effects of genotype combinations yielded similar results. These findings underscore the importance of assessing the collective effects of a panel of polymorphisms in the same pathway in modulating mutagen sensitivity. As risk assessment for cancer risk is moving toward a multigenic pathway-based approach, future genotype-phenotype correlation studies should also investigate the combined effects of multiple genetic variants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932354     DOI: 10.1158/1055-9965.EPI-06-1041

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  22 in total

1.  Germ line variation in nucleotide excision repair genes and lung cancer risk in smokers.

Authors:  Lori C Sakoda; Melissa M Loomis; Jennifer A Doherty; Liberto Julianto; Matt J Barnett; Marian L Neuhouser; Mark D Thornquist; Noel S Weiss; Gary E Goodman; Chu Chen
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-05

2.  Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer.

Authors:  Mary A Bewick; Robert M Lafrenie; Michael S C Conlon
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

3.  Nucleotide excision repair gene polymorphisms, meat intake and colon cancer risk.

Authors:  Susan E Steck; Lesley M Butler; Temitope Keku; Samuel Antwi; Joseph Galanko; Robert S Sandler; Jennifer J Hu
Journal:  Mutat Res       Date:  2014-03-07       Impact factor: 2.433

4.  Sensitivity to NNKOAc is associated with renal cancer risk.

Authors:  Jessica Clague; Lina Shao; Jie Lin; Shine Chang; Yimin Zhu; Wei Wang; Christopher G Wood; Xifeng Wu
Journal:  Carcinogenesis       Date:  2009-02-23       Impact factor: 4.944

5.  Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma.

Authors:  Jinliang Xing; Meng Chen; Christopher G Wood; Jie Lin; Margaret R Spitz; Jianzhong Ma; Christopher I Amos; Peter G Shields; Neal L Benowitz; Jian Gu; Mariza de Andrade; Gary E Swan; Xifeng Wu
Journal:  J Natl Cancer Inst       Date:  2008-07-29       Impact factor: 13.506

Review 6.  Pharmacogenomics of platinum-based chemotherapy in NSCLC.

Authors:  Michelle A T Hildebrandt; Jian Gu; Xifeng Wu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-07       Impact factor: 4.481

7.  Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study.

Authors:  Yun-Ling Zheng; Ourania Kosti; Christopher A Loffredo; Elise Bowman; Leah Mechanic; Donna Perlmutter; Raymond Jones; Peter G Shields; Curtis C Harris
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

8.  Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai.

Authors:  Hui Wen; Qiang Ding; Zu-jun Fang; Guo-wei Xia; Jie Fang
Journal:  Int Urol Nephrol       Date:  2009-04-07       Impact factor: 2.370

9.  Genetic polymorphisms in RAD23B and XPC modulate DNA repair capacity and breast cancer risk in Puerto Rican women.

Authors:  Julyann Pérez-Mayoral; Alba L Pacheco-Torres; Luisa Morales; Heidi Acosta-Rodríguez; Jaime L Matta; Julie Dutil
Journal:  Mol Carcinog       Date:  2013-06-18       Impact factor: 4.784

10.  Evaluating the association of polymorphisms in the HAP1 gene with lung cancer risk: a meta-analysis.

Authors:  Wei Wang; Haicheng Yan; Qiang Zhang; Wei Song; Haina Li; Jun Xu
Journal:  Tumour Biol       Date:  2014-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.